Adenovirus vaccine

From WikiProjectMed
Jump to navigation Jump to search

Adenovirus vaccine
Bottles of the vaccine
Vaccine description
Target diseaseAdenovirus
TypeLive virus
Clinical data
Main usesPrevent adenovirus infection[1]
Side effectsHeadache, runny nose, cough, joint pain, nausea, diarrhea[2]
  • US: N (Not classified yet)
Routes of
By mouth
External links
License data

Adenovirus vaccine is a vaccine against certain types of adenovirus infection.[1][3] Specifically it is effective against Type E4 and Type B7.[4] It is taken by mouth.[1]

Common side effects include headache, runny nose, cough, joint pain, nausea, and diarrhea.[2] Use in contraindicated in pregnancy.[2] It consists of live (not attenuated) virus.[2] The tablets are coated, so that the virus passes the stomach and infects the intestines, where immunity is raised.[2][5]

Adenovirus vaccine was approved for medical use by the United States military in the United States in 2011.[2] Prior versions were used by the military starting in the early 1960s.[6]


It was used by the United States military from 1971 to 1999, but was discontinued when the only manufacturer stopped production.[4] On March 16, 2011, the U.S. Food and Drug Administration approved an adenovirus vaccine manufactured by Teva Pharmaceuticals under contract to the U.S. Army.[7] This vaccine is essentially the same as the one used from 1971 to 1999. On October 24, 2011, the military services began administering the new adenovirus vaccine to recruits during basic training.[8]


It should not be confused with the strategy of using adenovirus as a viral vector to develop vaccines for other pathogens, or as a general gene carrier.[9][10][11]


  1. 1.0 1.1 1.2 "Adenovirus Vaccine Information Statement | CDC". 8 April 2021. Archived from the original on 14 August 2021. Retrieved 13 January 2022.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 "DailyMed - ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE, LIVE kit". Archived from the original on 1 December 2021. Retrieved 13 January 2022.
  3. Tucker SN, Tingley DW, Scallan CD (February 2008). "Oral adenoviral-based vaccines: historical perspective and future opportunity". Expert Rev Vaccines. 7 (1): 25–31. doi:10.1586/14760584.7.1.25. PMID 18251691. S2CID 7058518.
  4. 4.0 4.1 Flint, S. Jane; Nemerow, Glen R. (2017). "8. Pathogenesis". Human Adenoviruses: From Villains To Vectors. Singapore: World Scientific. p. 153-183. ISBN 978-981-310-979-7. Archived from the original on 5 May 2022. Retrieved 5 May 2022.
  5. "Adenovirus Vaccine Monograph for Professionals". Archived from the original on 25 July 2021. Retrieved 13 January 2022.
  6. Plotkin, Stanley A.; Orenstein, Walter A. (2008). Vaccines (Fourth ed.). Elsevier. p. 8. ISBN 978-1-4160-3611-1. Archived from the original on 11 January 2022. Retrieved 19 December 2021.
  7. Malarkey MA, Baylor NW. FDA approval letter dated March 16, 2011.
  8. Choudhry A, Mathena J, Albano JD, Yacovone M, Collins L (31 August 2016). "Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits". Vaccine. 34 (38): 4558–4564. doi:10.1016/j.vaccine.2016.07.033. PMID 27475474.
  9. Croyle MA, Patel A, Tran KN, et al. (2008). Doolan DL (ed.). "Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice". PLOS ONE. 3 (10): e3548. Bibcode:2008PLoSO...3.3548C. doi:10.1371/journal.pone.0003548. PMC 2569416. PMID 18958172.
  10. Hartman ZC, Appledorn DM, Amalfitano A (March 2008). "Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications". Virus Res. 132 (1–2): 1–14. doi:10.1016/j.virusres.2007.10.005. PMC 4039020. PMID 18036698.
  11. Tatsis N, Ertl HC (October 2004). "Adenoviruses as vaccine vectors". Mol. Ther. 10 (4): 616–29. doi:10.1016/j.ymthe.2004.07.013. PMC 7106330. PMID 15451446.

External links